about
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domainCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsDetermination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imagingNon-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium.A proteomic approach for the identification of vascular markers of liver metastasis.Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells.Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host.The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaA ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.Preclinical development of metalloproteasis inhibitors in cancer therapy.High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.Anticancer therapy with angiogenesis inhibitors.Small molecules in anti-angiogenic therapy.Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.IDN 5390: a new concept in taxane development.Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signallingMetastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumoursCisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.Vascular endothelium summary statement III: Cancer prevention and control.Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds.Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.Angiogenesis inhibitors: implications for combination with conventional therapies.Targeting angiogenesis with compounds from the extracellular matrix.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Intratumor heterogeneity and its impact on drug distribution and sensitivity.Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues.Antiangiogenic activity of aplidine, a new agent of marine origin
P50
Q24300120-24A6F002-00A9-47FC-96FA-A10BFD7D42D7Q26746067-89153873-C466-4379-AC32-1E320E93F588Q28535605-B1D82A79-7232-453C-968C-8FA054E3670CQ30493655-5CC1B052-AD5B-4D05-8D1F-2AB7A2399951Q30843102-D7199F76-8D32-42AB-85A3-90B0223FD1A5Q30968545-E09A5577-2325-450E-84BB-834DCD075486Q31983397-E6E14C8C-4639-4C92-93B7-003F4963666FQ33207855-A369D315-E17D-46A7-88F2-FDBE51B24061Q33459019-9008C5C0-0206-44FC-B284-D28324E4A044Q33487344-6DFAA4C8-BD61-4BFE-9E93-860AE5AEFF6BQ33514437-A6688B3F-F6A1-4566-895B-1FBBB7D1AE87Q33907027-52910C3B-70A9-4004-97B6-97402307284AQ34133632-D2B8DAD2-219A-420E-855A-FEA79D68DA36Q34506115-DE9D8158-1545-42C1-AE82-1ACD4AF647DAQ34624211-5BDD5E0D-76C6-42CF-8CA8-354F05E9B9CDQ34675686-5F88813C-1A79-48AB-ACCF-E06A48DD684AQ34785151-F0577031-3AC6-436D-8890-396B7CD9504EQ35052151-82A7C318-0BC8-403C-AF95-90C18399F6D4Q35101284-6DEDF3D3-D1E8-482D-B48C-1722BDA97711Q35550169-172DC6D5-2FC0-4296-86C0-60999E6177A4Q35791487-C664A320-AF21-4CB7-943A-D03BB3A1C54EQ35818315-77F58C4C-7F86-4D61-8360-E816FFC3B537Q35823514-BC61B6BB-6018-4D0D-91AF-A1820D2B0853Q36012858-4B974FE8-B4BC-4278-A8F7-2F2F77E03B23Q36038778-0B1777FF-1057-4F72-9072-68B9F2A30F6DQ36044320-B62C65CC-4DA3-446A-B0C3-A0CCB77F8D36Q36089989-156137EA-F2ED-4FC5-8FE8-F9E9ACE2278AQ36223338-019B655D-B4FB-484A-846E-3052516268B3Q36282749-5FD02763-4710-4277-B6FC-5798F45D6063Q36389313-6802F10E-02D6-4F1B-9766-8E688C40ADFDQ36611295-14ADCFB9-E230-4AF3-A614-DB453577EF0BQ36711870-7431A5C5-2A37-43EB-8063-388A98042EB0Q36951737-8F39D814-1D29-472B-AC13-15DFB623E815Q37522770-68E6FCF8-070E-41ED-9456-28C8F61FA8D8Q37821032-3586F37C-7FDE-4F48-AFC9-32DE5B56D7D3Q37921881-3AC5F2E2-6BCE-48F5-9B4A-D16C81C90A4EQ38150356-CE00B678-2795-4301-B6D0-E2816A337868Q38211694-970CAED2-845A-49EC-9460-45A02750E156Q38347356-6C0BDE1B-E2A1-465B-8EB6-E98F4EB9A4F0Q38796073-84684D74-EEF6-4EA7-B960-9D3C29D0F566
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raffaella Giavazzi
@ast
Raffaella Giavazzi
@en
Raffaella Giavazzi
@es
Raffaella Giavazzi
@nl
Raffaella Giavazzi
@sl
type
label
Raffaella Giavazzi
@ast
Raffaella Giavazzi
@en
Raffaella Giavazzi
@es
Raffaella Giavazzi
@nl
Raffaella Giavazzi
@sl
prefLabel
Raffaella Giavazzi
@ast
Raffaella Giavazzi
@en
Raffaella Giavazzi
@es
Raffaella Giavazzi
@nl
Raffaella Giavazzi
@sl
P106
P21
P31
P496
0000-0001-5249-8208